Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations.

Next Previous
X
Search
Trial Profile

An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Uterine cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 Sep 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 24 Jan 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 19 Nov 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top